Frontiers in Pharmacology (Feb 2022)
Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
- Jianhong Yang,
- Xiaoyu Zhao,
- Jie Li,
- Kejian Zhang,
- Kejian Zhang,
- Kejian Zhang,
- Zheru Zhang,
- Shunwen Chang,
- Daotian Fu,
- Xinhuan Lyu,
- Xianglin Zhang,
- Ying Shao
Affiliations
- Jianhong Yang
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- Xiaoyu Zhao
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- Jie Li
- Overland Pharma (Shanghai) Limited Company, Shanghai, China
- Kejian Zhang
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- Kejian Zhang
- School of Pharmaceuticals, Sun Yat-sen University, Guangzhou, China
- Kejian Zhang
- South China Center for Innovative Pharmaceuticals, Guangdong, China
- Zheru Zhang
- I-Mab, Shanghai, China
- Shunwen Chang
- Skyline Therapeutics, Shanghai, China
- Daotian Fu
- RemeGen, Ltd., Shandong, China
- Xinhuan Lyu
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- Xianglin Zhang
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- Ying Shao
- Research center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China
- DOI
- https://doi.org/10.3389/fphar.2022.815074
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
